The announcement of interim data from the Phase I/II trial of AMT-130 in Huntington's Disease has led to a decline in uniQure's share price. This is likely due to investors reacting to the news and adjusting their positions based on the trial's progress. The impact on the stock price is expected to be short-term as the market digests the information.